Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 85 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: extended release metformin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food

NCT02039258
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CANA/MET XR FDC
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women

NCT02338193
View directory record Official record
Conditions
Diabetes Prevention in Women After GDM Who Are at High-risk
Interventions
DAPA/MET XR, DAPA, MET XR
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 30, 2026, 4:45 AM EDT
Active, not recruiting Phase 2 Interventional

Metformin and Nightly Fasting in Women With Early Breast Cancer

NCT05023967
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Interventions
Biospecimen Collection, Extended Release Metformin Hydrochloride, Monitoring, Nutritional Assessment, Short-Term Fasting
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 2 Interventional Results available

Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

NCT01433913
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
metformin hydrochloride, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Tucson, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 30, 2026, 4:45 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Metformin in Alzheimer's Dementia Prevention

NCT04098666
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Placebo oral tablet, extended release metformin
Drug
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 90 Years
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
22
States / cities
Irvine, California • Palo Alto, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 2 Interventional Results available

Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus

NCT01447927
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Cancer
Interventions
metformin hydrochloride, placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Hines, Illinois • Rochester, Minnesota • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Metformin HCl 750 mg XR Tablets Under Non Fasting Conditions

NCT00778141
View directory record Official record
Conditions
Healthy
Interventions
metformin HC1 750 mg extended-release tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851212
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Metformin HCl 750 mg XR Under Fasting Conditions

NCT00778791
View directory record Official record
Conditions
Healthy
Interventions
metformin HC1 750 mg extended-release tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions

NCT00865852
View directory record Official record
Conditions
Healthy
Interventions
Metformin HCl 750 mg Extender Release tablets, single dose, GLUCOPHAGE® XR 750 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

NCT01975220
View directory record Official record
Conditions
Healthy
Interventions
Empagliflozin/Metformin XR FDC, 25 mg Empagliflozin/1000 mg Metformin XR, FDC, 1 tablet Empagliflozin/2 tablets Metformin XR, 1 tablet Empagliflozin/3 tablets Metformin XR
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

NCT02071368
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin, 300 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 150 mg/500, CANA/MET XR FDC, Formulation 2, 150 mg/500 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

NCT00643851
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Haleyville, Alabama • Tempe, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 4 Interventional Results available

Ranolazine and Microvascular Angina by PET in the Emergency Department

NCT02052011
View directory record Official record
Conditions
Microvascular Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
30 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 30, 2026, 4:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

AMPK-activation by Metformin in FSGS: AMP-FSGS

NCT06090227
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Metformin + Standard of Care, Placebo + Standard of Care
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 30, 2026, 4:45 AM EDT
Active, not recruiting Not applicable Interventional

Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)

NCT05040087
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Intensification of diabetes medication based largely on HbA1c levels, Intensification of diabetes medication based on glucose levels
Other
Lead sponsor
Foundation for Atlanta Veterans Education and Research, Inc.
Other
Eligibility
40 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vaccination Efficacy With Metformin in Older Adults

NCT03996538
View directory record Official record
Conditions
Aging, Age-Related Immunodeficiency, Vaccine Response Impaired
Interventions
Metformin Hydrochloride Extended-Release Tablets, Influenza Vaccine
Drug · Biological
Lead sponsor
UConn Health
Other
Eligibility
65 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 30, 2026, 4:45 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

NCT05237960
View directory record Official record
Conditions
Erythroplakia, Oral Leukoplakia
Interventions
Biopsy, Biospecimen Collection, Extended Release Metformin Hydrochloride, Placebo Administration
Procedure · Drug
Lead sponsor
University of Arizona
Other
Eligibility
21 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Tucson, Arizona • San Diego, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 4:45 AM EDT
Recruiting Phase 2 Interventional

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

NCT06273072
View directory record Official record
Conditions
Asthma, Asthma Chronic, Overweight and Obesity
Interventions
Metformin hydrochloride extended-release tablets, Visually identical placebo Metformin hydrochloride extended-release tablets
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasting Conditions

NCT00865072
View directory record Official record
Conditions
Healthy
Interventions
Metformin HCl 750 mg Extender Release tablets, single dose, GLUCOPHAGE® XR 750 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 30, 2026, 4:45 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Oral Metformin for Treatment of ABCA4 Retinopathy

NCT04545736
View directory record Official record
Conditions
ABCA4 Retinopathy, Stargardt Disease, Retinal Dystrophy, Retinal Degeneration
Interventions
Metformin hydrochloride
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
12 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Bethesda, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 4 Interventional Results available

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

NCT01864174
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin XR, Metformin IR, Placebo matching with Metformin XR, Placebo matching with Metformin IR
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
39
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 30, 2026, 4:45 AM EDT
Recruiting Phase 1 Interventional

Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia

NCT07901959
View directory record Official record
Conditions
Fanconi Anemia, Head and Neck Cancer, Squamous Cell Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN)
Interventions
Metformin, Naproxen Sodium
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 4:45 AM EDT
Completed Phase 2 Interventional

Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction

NCT05093959
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Metformin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 30, 2026, 4:45 AM EDT